EX3 Investigating Time to Next Treatment As a Surrogate Endpoint for Overall Survival in Previously Untreated Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma Patients: An Insight from the Phase III CheckMate-214
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.028
https://www.valueinhealthjournal.com/article/S1098-3015(20)32284-1/fulltext
Title :
EX3 Investigating Time to Next Treatment As a Surrogate Endpoint for Overall Survival in Previously Untreated Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma Patients: An Insight from the Phase III CheckMate-214
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32284-1&doi=10.1016/j.jval.2020.08.028
First page :
Section Title :
Open access? :
No
Section Order :
10018